{"id":43421,"date":"2021-04-02T12:08:23","date_gmt":"2021-04-02T10:08:23","guid":{"rendered":"https:\/\/newserver.fyb.de\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/"},"modified":"2021-04-02T12:08:23","modified_gmt":"2021-04-02T10:08:23","slug":"baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/","title":{"rendered":"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale"},"content":{"rendered":"

Berlin \u2014 The Chinese company Sino Biophar\u00admaceu\u00adti\u00adcal Limi\u00adted is buying Softhale NV. Softhale is a priva\u00adtely held Belgian company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of products for the treat\u00adment of respi\u00adra\u00adtory dise\u00ada\u00adses. Its next-gene\u00adra\u00adtion Soft Mist Inha\u00adla\u00adtion (\u201cSMI\u201d) device is based on diffe\u00adren\u00adtia\u00adted tech\u00adno\u00adlogy and enables more effi\u00adci\u00adent drug depo\u00adsi\u00adtion in the lungs.<\/p>\n

The tran\u00adsac\u00adtion volume is USD 110 million<\/strong> and addi\u00adtio\u00adnal payments rela\u00adted to regu\u00adla\u00adtory and commer\u00adcial milestones.<\/p>\n

An inter\u00adna\u00adtio\u00adnal team of Baker McKen\u00adzie lawy\u00aders provi\u00added compre\u00adhen\u00adsive advice to Sino Biophar\u00admaceu\u00adti\u00adcal Limi\u00adted on all legal and regu\u00adla\u00adtory aspects of the tran\u00adsac\u00adtion, with the agree\u00adment gover\u00adned by German law. The M&A nego\u00adtia\u00adti\u00adons were led by Dr. Thors\u00adten Seidel<\/strong> in Berlin. The due dili\u00adgence on the Belgian company was led by Baker McKen\u00adzie Brussels under the leader\u00adship of Domi\u00adni\u00adque Maes.<\/p>\n

\u201cWith the successful closing of the tran\u00adsac\u00adtion, we were able to support our client in the imple\u00admen\u00adta\u00adtion of its growth stra\u00adtegy. With this acqui\u00adsi\u00adtion, our client gains a stra\u00adte\u00adgic hub in Europe on its way to beco\u00adming a major deve\u00adlo\u00adper of inno\u00adva\u00adtive respi\u00adra\u00adtory products for China and the global market,\u201d commen\u00adted Dr. Thors\u00adten Seidel, Part\u00adner Baker McKenzie.<\/p>\n

Sino Biophar\u00admaceu\u00adti\u00adcal, toge\u00adther with its subsi\u00addia\u00adries, is a leading inno\u00adva\u00adtive rese\u00adarch and deve\u00adlo\u00adp\u00adment (\u201cR&D\u201d) focu\u00adsed phar\u00admaceu\u00adti\u00adcal conglo\u00adme\u00adrate in China. Sino Biophar\u00admaceu\u00adti\u00adcal\u2019s busi\u00adness compri\u00adses a fully inte\u00adgra\u00adted chain of phar\u00admaceu\u00adti\u00adcal products that includes a number of inno\u00adva\u00adtive R&D plat\u00adforms and pipe\u00adlines, a range of smart manu\u00adfac\u00adtu\u00adring faci\u00adli\u00adties, and a strong distri\u00adbu\u00adtion infrastructure.<\/p>\n

Softhale is a Belgian phar\u00admaceu\u00adti\u00adcal company specia\u00adli\u00adzing in the deve\u00adlo\u00adp\u00adment of SMI (Soft Mist Inha\u00adla\u00adtion) devices (vapor inha\u00adlers) and rela\u00adted phar\u00admaceu\u00adti\u00adcal products for the deli\u00advery of drugs to the lungs.<\/p>\n

Baker McKen\u00adzie\u2019s global Corporate\/M&A team advi\u00adses on more cross-border tran\u00adsac\u00adtions than any other law firm. Most recently, Baker McKen\u00adzie advi\u00adsed Para\u00adgon on the sale of Novu\u00admIP to Ques\u00adtel Group, TA Asso\u00adcia\u00adtes on the acqui\u00adsi\u00adtion of a majo\u00adrity stake in IGEL, Embra\u00adcer on the acqui\u00adsi\u00adtion of Easy\u00adbrain Limi\u00adted, SK Tele\u00adcom on a joint venture with Deut\u00adsche Tele\u00adkom, Chr. Hansen Holding A\/S in its acqui\u00adsi\u00adtion of Jenne\u00adwein Biotech\u00adno\u00adlo\u00adgie GmbH, DBAG in an invest\u00adment in conga\u00adtec Holding AG, SAP in the sale of its SAP Digi\u00adtal Inter\u00adcon\u00adnect commu\u00adni\u00adca\u00adti\u00adons unit to Sinch AB, Air Liquide in the sale of the Sch\u00fclke Group to Swedish finan\u00adcial inves\u00adtor EQT, METRO AG in the sale of its China busi\u00adness and the estab\u00adlish\u00adment of a stra\u00adte\u00adgic part\u00adner\u00adship with Wumei, Bayer AG in the sale of its majo\u00adrity stake in chemi\u00adcal park opera\u00adtor Currenta, and Evonik in the sale of its methacry\u00adla\u00adtes group to Advent International.<\/p>\n

Legal advi\u00adsor Sino Biophar\u00admaceu\u00adti\u00adcal Limi\u00adted: Baker McKenzie<\/strong>
\nLead: Corporate\/M&A: Dr. Thors\u00adten Seidel (Part\u00adner, Berlin)
\nOther lawy\u00aders invol\u00adved: Corporate\/M&A: Domi\u00adni\u00adque Maes (Part\u00adner, Brussels), Kim Stas (Coun\u00adsel, Brussels), Derek Poon (Part\u00adner, Hong Kong), Bruno Schro\u00e9 (Asso\u00adciate, Brussels), Holger Engel\u00adkamp (Coun\u00adsel, Berlin)
\nEmploy\u00adment: Dr. Matthias K\u00f6hler (Part\u00adner, Berlin), Tatjana Serbina (Asso\u00adciate, Berlin)
\nIP: Dr. Rembert Niebel (Part\u00adner, Frankfurt)<\/p>\n

About Baker McKenzie<\/p>\n

Baker McKen\u00adzie advi\u00adses clients to successfully deal with the chal\u00adlenges of globa\u00adliza\u00adtion. We solve complex legal problems across natio\u00adnal borders and legal fields. Our unique culture \u2014 grown over 70 years \u2014 enables our 13,000 employees to under\u00adstand local markets while opera\u00adting inter\u00adna\u00adtio\u00adnally. We use the trus\u00adting and friendly coope\u00adra\u00adtion in our inter\u00adna\u00adtio\u00adnal network for the bene\u00adfit of our clients.<\/p>\n

In Germany, around 200 lawy\u00aders with proven profes\u00adsio\u00adnal exper\u00adtise and inter\u00adna\u00adtio\u00adnal expe\u00adri\u00adence repre\u00adsent the inte\u00adrests of their clients at the offices in Berlin, D\u00fcssel\u00addorf, Frankfurt\/Main and Munich. As one of the leading German law firms, Baker McKen\u00adzie advi\u00adses natio\u00adnal and inter\u00adna\u00adtio\u00adnal compa\u00adnies and insti\u00adtu\u00adti\u00adons in all areas of commer\u00adcial law.<\/p>\n","protected":false},"excerpt":{"rendered":"

Berlin \u2014 The Chinese company Sino Biophar\u00admaceu\u00adti\u00adcal Limi\u00adted is buying Softhale NV. Softhale is a priva\u00adtely held Belgian company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of products for the treat\u00adment of respi\u00adra\u00adtory dise\u00ada\u00adses. Its next-gene\u00adra\u00ad\u00adtion Soft Mist Inha\u00adla\u00adtion (\u201cSMI\u201d) device is based on diffe\u00adren\u00adtia\u00adted tech\u00adno\u00adlogy and enables more effi\u00adci\u00adent drug depo\u00adsi\u00adtion in the lungs. The tran\u00adsac\u00adtion volume is [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37069,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1371,1372],"tags":[],"class_list":["post-43421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-deals-en","category-consultant","news-category-deals-news-en"],"yoast_head":"\nBaker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Berlin \u2014 The Chinese company Sino Biophar\u00admaceu\u00adti\u00adcal Limi\u00adted is buying Softhale NV. Softhale is a priva\u00adtely held Belgian company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of products for the treat\u00adment of respi\u00adra\u00adtory dise\u00ada\u00adses. Its next-gene\u00adra\u00adtion Soft Mist Inha\u00adla\u00adtion (\u201cSMI\u201d) device is based on diffe\u00adren\u00adtia\u00adted tech\u00adno\u00adlogy and enables more effi\u00adci\u00adent drug depo\u00adsi\u00adtion in the lungs. The tran\u00adsac\u00adtion volume is […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-02T10:08:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"850\" \/>\n\t<meta property=\"og:image:height\" content=\"478\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale\",\"datePublished\":\"2021-04-02T10:08:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Lawyers, tax consultants, auditors\",\"DEALS\",\"Consultant\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\",\"url\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\",\"name\":\"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg\",\"datePublished\":\"2021-04-02T10:08:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg\",\"width\":850,\"height\":478,\"caption\":\"Sino Biopharmaceutical Limited\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/","og_locale":"en_US","og_type":"article","og_title":"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale - FYB Financial Yearbook","og_description":"Berlin \u2014 The Chinese company Sino Biophar\u00admaceu\u00adti\u00adcal Limi\u00adted is buying Softhale NV. Softhale is a priva\u00adtely held Belgian company focu\u00adsed on the deve\u00adlo\u00adp\u00adment of products for the treat\u00adment of respi\u00adra\u00adtory dise\u00ada\u00adses. Its next-gene\u00adra\u00adtion Soft Mist Inha\u00adla\u00adtion (\u201cSMI\u201d) device is based on diffe\u00adren\u00adtia\u00adted tech\u00adno\u00adlogy and enables more effi\u00adci\u00adent drug depo\u00adsi\u00adtion in the lungs. The tran\u00adsac\u00adtion volume is […]","og_url":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2021-04-02T10:08:23+00:00","og_image":[{"width":850,"height":478,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale","datePublished":"2021-04-02T10:08:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/"},"wordCount":608,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg","articleSection":["General","Featured","News","Lawyers\/Tax-advisors\/Auditors","Lawyers, tax consultants, auditors","DEALS","Consultant"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/","url":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/","name":"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg","datePublished":"2021-04-02T10:08:23+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/04\/a-sino.jpeg","width":850,"height":478,"caption":"Sino Biopharmaceutical Limited"},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/baker-mckenzie-advises-sino-biopharmaceutical-on-acquisition-of-softhale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Baker McKenzie advises Sino Biopharmaceutical on acquisition of Softhale"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43421"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/37069"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}